Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 4 Diagram of various known microbes and the present pathogen On the basis of morphologic features, the microbes could be categorized into 5 groups:

Published byPatrick Skinner Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 4 Diagram of various known microbes and the present pathogen On the basis of morphologic features, the microbes could be categorized into 5 groups:"— Presentation transcript:

1 Figure 4 Diagram of various known microbes and the present pathogen On the basis of morphologic features, the microbes could be categorized into 5 groups: virus, bacteria, fungi, protozoa, and archaea. Diagram of various known microbes and the present pathogen On the basis of morphologic features, the microbes could be categorized into 5 groups: virus, bacteria, fungi, protozoa, and archaea. The present pathogen is characterized by irregular shape, varying size (2–7 μm), a membrane structure, and absence of both cell wall and nucleus. These morphologic features are distinguishable from those of viruses (diameter 0.02–0.3 μm), known pathogenic bacteria (with a cell wall or differences in size), fungi (with a cell wall and nucleus), or protozoa (with a nucleus) but analogous to 2 types of archaea, Thermoplasma and Ignicoccus. Yusuke Sakiyama et al. Neurol Neuroimmunol Neuroinflamm 2015;2:e143 © 2015 American Academy of Neurology

Download ppt "Figure 4 Diagram of various known microbes and the present pathogen On the basis of morphologic features, the microbes could be categorized into 5 groups:"

Similar presentations

Prokaryotic and Eukaryotic

Prokaryotic and Eukaryotic
Figure 4 Number of subjects with positive DTH response to recall antigens before and at the end of treatmentA positive delayed-type hypersensitivity (DTH)

Figure 4 Number of subjects with positive DTH response to recall antigens before and at the end of treatmentA positive delayed-type hypersensitivity (DTH)
Figure 2 ALSFRS-R changes (A) Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) slope after 6 months of treatment without (left)

Figure 2 ALSFRS-R changes (A) Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) slope after 6 months of treatment without (left)
Figure 3 Brain MRI findings in patients with MOG-Ab Extensive brain lesions with large diameter (A and B), posterior reversible encephalopathy–like lesions.

Figure 3 Brain MRI findings in patients with MOG-Ab Extensive brain lesions with large diameter (A and B), posterior reversible encephalopathy–like lesions.
Figure 1 Box plot of the venous diameter in lesions

Figure 1 Box plot of the venous diameter in lesions
Figure 1 Stiff-person syndrome spectrum patient serum bound to membranes of live GlyRα1-transfected HEK293 cells Stiff-person syndrome spectrum patient.

Figure 1 Stiff-person syndrome spectrum patient serum bound to membranes of live GlyRα1-transfected HEK293 cells Stiff-person syndrome spectrum patient.
Figure 2. Change in total PSPRS score from baseline to each study visit for all participants Change in total PSPRS score from baseline to each study visit.

Figure 2. Change in total PSPRS score from baseline to each study visit for all participants Change in total PSPRS score from baseline to each study visit.
Figure 3 Immunohistochemical analyses of positive and negative Epstein-Barr virus (EBV) control tissues using immunostaining Immunohistochemical analyses.

Figure 3 Immunohistochemical analyses of positive and negative Epstein-Barr virus (EBV) control tissues using immunostaining Immunohistochemical analyses.
Figure 2 Anti-LINGO-1 (Li81) does not affect cytokine production

Figure 2 Anti-LINGO-1 (Li81) does not affect cytokine production
Figure 1 Treg percentage and suppressive function increased during each round of Treg infusions Treg percentage and suppressive function increased during.

Figure 1 Treg percentage and suppressive function increased during each round of Treg infusions Treg percentage and suppressive function increased during.
Figure 3 Immune response to neoantigen: Geometric mean titers of antirabies antibody levels over timeAt days 31 and 38, all subjects achieved antibody.

Figure 3 Immune response to neoantigen: Geometric mean titers of antirabies antibody levels over timeAt days 31 and 38, all subjects achieved antibody.
Figure 3 JCV index changes in JCV+ patients

Figure 3 JCV index changes in JCV+ patients
Figure 1 Flow diagram of the assays and the samples that were evaluatedA total of 1,109 samples were initially screened at a serum dilution of 1:20 for.

Figure 1 Flow diagram of the assays and the samples that were evaluatedA total of 1,109 samples were initially screened at a serum dilution of 1:20 for.
Figure 1 Cerebral MRI during the disease course Cerebral MRI with multiple cerebral supratentorial lesions during the disease course: periventricular lesions.

Figure 1 Cerebral MRI during the disease course Cerebral MRI with multiple cerebral supratentorial lesions during the disease course: periventricular lesions.
Figure 5 Increased frequency of parenchymal CD138- and LMP-1–positive cells in MS Increased frequency of parenchymal CD138- and LMP-1–positive cells in.

Figure 5 Increased frequency of parenchymal CD138- and LMP-1–positive cells in MS Increased frequency of parenchymal CD138- and LMP-1–positive cells in.
Figure 1 MOR103 sequential-dose trial flowchart of study population with multiple sclerosis aPatients received 2 doses of study drug before trial withdrawal.

Figure 1 MOR103 sequential-dose trial flowchart of study population with multiple sclerosis aPatients received 2 doses of study drug before trial withdrawal.
Figure 3 Stepwise strategy of bioinformatic analysis of sequencing results We obtained 7,292,715 and 303,698 DNA sequence reads from the affected brain.

Figure 3 Stepwise strategy of bioinformatic analysis of sequencing results We obtained 7,292,715 and 303,698 DNA sequence reads from the affected brain.
Figure 2 Exemplary MRI of a patient with contrast enhancement on postcontrast FLAIR MRI of a 54-year-old patient with viral meningitis caused by varicella-zoster.

Figure 2 Exemplary MRI of a patient with contrast enhancement on postcontrast FLAIR MRI of a 54-year-old patient with viral meningitis caused by varicella-zoster.
Figure 2 Mean serum concentrations of BIIB033 vs time(A) Single ascending dose study and (B) multiple ascending dose study. Mean serum concentrations of.

Figure 2 Mean serum concentrations of BIIB033 vs time(A) Single ascending dose study and (B) multiple ascending dose study. Mean serum concentrations of.
Figure 1 Peripheral blood leukocyte subset counts during dimethyl fumarate treatmentComplete blood cell counts were obtained at baseline (n = 34) and at.

Figure 1 Peripheral blood leukocyte subset counts during dimethyl fumarate treatmentComplete blood cell counts were obtained at baseline (n = 34) and at.

Similar presentations

Ads by Google